Stock Track | TransMedics Group Soars 6.12% in Pre-Market as Company Rebuts Short-Seller Claims and Touts Growth Outlook

Stock Track

Jan 14

TransMedics Group, Inc. (TMDX) saw its stock price soar 6.12% in the pre-market trading session on Tuesday, following the company's robust response to an inaccurate and misleading short-seller report issued by Scorpion Capital.

TransMedics vehemently denied the claims made in the report, asserting that it failed to accurately represent the company's business, technology, and focus on delivering products and services for organ transplantation. The company highlighted that its OCS technology and NOP program have enabled over 7,000 organ transplants, allowing surgeons to utilize donor organs that would have otherwise been unutilized. TransMedics defended the integrity of its practices, team, compliance, and commitment to improving clinical outcomes.

The company's technology and services have driven an expansion in overall U.S. transplant volumes and exceptional post-transplant clinical outcomes, as validated by its extensive clinical data set. Investors appear to be responding positively to TransMedics' strong rebuttal and reiteration of its growth prospects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1182210853"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1182210853\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1182210853?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-14 17:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182210853","market":"hk","top_or_hot":-1,"title":"Stock Track | TransMedics Group Soars 6.12% in Pre-Market as Company Rebuts Short-Seller Claims and Touts Growth Outlook","media":"Stock Track","content":"<p>TransMedics Group, Inc. (TMDX) saw its stock price soar 6.12% in the pre-market trading session on Tuesday, following the company's robust response to an inaccurate and misleading short-seller report issued by Scorpion Capital.</p>\n\n<p>TransMedics vehemently denied the claims made in the report, asserting that it failed to accurately represent the company's business, technology, and focus on delivering products and services for organ transplantation. The company highlighted that its OCS technology and NOP program have enabled over 7,000 organ transplants, allowing surgeons to utilize donor organs that would have otherwise been unutilized. TransMedics defended the integrity of its practices, team, compliance, and commitment to improving clinical outcomes.</p>\n\n<p>The company's technology and services have driven an expansion in overall U.S. transplant volumes and exceptional post-transplant clinical outcomes, as validated by its extensive clinical data set. Investors appear to be responding positively to TransMedics' strong rebuttal and reiteration of its growth prospects.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | TransMedics Group Soars 6.12% in Pre-Market as Company Rebuts Short-Seller Claims and Touts Growth Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | TransMedics Group Soars 6.12% in Pre-Market as Company Rebuts Short-Seller Claims and Touts Growth Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-01-14 17:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TransMedics Group, Inc. (TMDX) saw its stock price soar 6.12% in the pre-market trading session on Tuesday, following the company's robust response to an inaccurate and misleading short-seller report issued by Scorpion Capital.</p>\n\n<p>TransMedics vehemently denied the claims made in the report, asserting that it failed to accurately represent the company's business, technology, and focus on delivering products and services for organ transplantation. The company highlighted that its OCS technology and NOP program have enabled over 7,000 organ transplants, allowing surgeons to utilize donor organs that would have otherwise been unutilized. TransMedics defended the integrity of its practices, team, compliance, and commitment to improving clinical outcomes.</p>\n\n<p>The company's technology and services have driven an expansion in overall U.S. transplant volumes and exceptional post-transplant clinical outcomes, as validated by its extensive clinical data set. Investors appear to be responding positively to TransMedics' strong rebuttal and reiteration of its growth prospects.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TMDX","symbol_name":"TransMedics Group Inc.","start_time":0,"source_url":"","article_id":"1182210853","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182210853","pubTimestamp":1736846897,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"TransMedics Group, Inc.  saw its stock price soar 6.12% in the pre-market trading session on Tuesday, following the company's robust response to an inaccurate and misleading short-seller report issued by Scorpion Capital.TransMedics vehemently denied the claims made in the report, asserting that it failed to accurately represent the company's business, technology, and focus on delivering products and services for organ transplantation. The company highlighted that its OCS technology and NOP prog","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TMDX":"TransMedics Group Inc."},"translate_title":"TransMedics Group反驳卖空者的说法并宣扬增长前景，股价盘前飙升6.12%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TMDX":1},"content_text":"TransMedics Group, Inc. (TMDX) saw its stock price soar 6.12% in the pre-market trading session on Tuesday, following the company's robust response to an inaccurate and misleading short-seller report issued by Scorpion Capital.\nTransMedics vehemently denied the claims made in the report, asserting that it failed to accurately represent the company's business, technology, and focus on delivering products and services for organ transplantation. The company highlighted that its OCS technology and NOP program have enabled over 7,000 organ transplants, allowing surgeons to utilize donor organs that would have otherwise been unutilized. TransMedics defended the integrity of its practices, team, compliance, and commitment to improving clinical outcomes.\nThe company's technology and services have driven an expansion in overall U.S. transplant volumes and exceptional post-transplant clinical outcomes, as validated by its extensive clinical data set. Investors appear to be responding positively to TransMedics' strong rebuttal and reiteration of its growth prospects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}